Abstract:CONTEXT: The use of systemic estrogens for the treatment of menopausal symptoms has declined by approximately 80% following the initial publication of the Women's Health Initiative in 2002. Current attention focuses on vaginal estrogen as a local therapeutic means to achieve control of symptoms due to vulvovaginal atrophy without increasing plasma estradiol levels. A key issue is whether or not vaginally administered estrogens are absorbed and produce systemic effects.EVIDENCE ACQUISITION: Medline and PubMed were searched for relevant English-language articles using pertinent key words. The bibliographies of the pertinent articles were then read to identify further relevant articles.EVIDENCE SYNTHESIS: Several confounding factors influenced the data analysis including: (1) estradiol assay sensitivity and specificity; (2) acute versus chronic absorption; (3) delivery systems, doses, timing, and formulation; and (4) effect of atrophic versus mature vaginal mucosa on absorption. Each preparation was associated with acute estradiol absorption with peaks at approximately 8 h and return to baseline at 12 h. Low-dose vaginal estrogen, arbitrarily defined as the 7.5-μg vaginal ring and 10-μg tablet, increased plasma estradiol levels during chronic administration but not above the normal range of ≤ 20 pg/ml. Surprisingly, these increments were associated with systemic effects to lower plasma levels of low density lipoprotein cholesterol and bone resorption rates. Intermediate doses (i.e. 25 μg estradiol or 0.3 mg conjugated equine estrogen) resulted in plasma estradiol levels approaching or exceeding 20 pg/ml. The higher doses (50-2000 μg estradiol or 0.625-2.5 mg conjugated equine estrogen) resulted in premenopausal levels of estrogen.CONCLUSIONS: Low-dose vaginal estrogen appears to be an effective strategy for managing women whose symptoms result from vulvovaginal atrophy. These regimens limit but do not completely eliminate systemic absorption. Low-doses regimens should be preferred clinically to intermediate- or high-dose methods.

Locally administered nanosuspension increases delivery of estradiol for the treatment of vaginal atrophy in mice

Hypotonic, gel-forming delivery system for vaginal drug administration

Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet

Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets

Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women

THE INVESTIGATION OF PHARMACOLOGICAL PROPERTIES OF VAGINAL GEL WITH RESVERATROL AND HYALURONIC ACID IN CONDITIONS OF EXPERIMENTAL HYPOESTROGENIC STATE IN RATS

Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels

Progesterone-loaded nanosized transethosomes for vaginal permeation enhancement: formulation, statistical optimization, and clinical evaluation in anovulatory polycystic ovary syndrome

Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy

Sustained estradiol valerate delivery by microneedles: A new effective platform to construct estrogen-dependent tumor model

Cell-Free Fat Extract Prevents Vaginal Atrophy in an Ovariectomized Model by Promoting Proliferation of Vaginal Keratinocytes and Neovascularization

Treatment of postmenopausal vulvovaginal atrophy with estriol: a scientific update for 2014–2018

Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy

Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study

The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study

The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review

Cellular and extracellular vaginal changes following murine ovarian removal

The Use of Cisplatin-Loaded Mucoadhesive Nanofibers for Local Chemotherapy of Cervical Cancers in Mice.

Efficacy of lipid nanoparticles-based vaccine to protect against vulvovaginal candidiasis (VVC): Implications for women's reproductive health

Beta-Cyclodextrin Modified Mesoporous Bioactive Glass Nanoparticles/Silk Fibroin Hybrid Nanofibers As An Implantable Estradiol Delivery System For The Potential Treatment Of Osteoporosis

Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer